A New Chapter: The Settlement Offer
In late July 2026, Johnson & Johnson announced a proposal that could finally draw a line under more than a decade of litigation. The company offered to pay approximately $5.5 billion to resolve the vast majority of claims from women who allege its talc-based
baby powder caused their ovarian cancer. This move signaled a significant change in tactics, moving away from the controversial bankruptcy strategy it had pursued for years. Unlike previous attempts, this offer was reached through direct negotiation with lawyers representing the claimants. However, the deal is not yet final. It is contingent on at least 95% of the tens of thousands of claimants agreeing to the terms, a high bar designed to ensure the resolution is comprehensive and final.
The Bankruptcy Gamble
For years, J&J’s primary strategy for managing the tens of thousands of lawsuits was a complex legal maneuver known as the "Texas two-step." In 2021, the company executed a corporate restructuring, creating a new subsidiary, LTL Management, and transferring all of its talc-related liabilities onto this new entity. Immediately after its creation, LTL Management filed for Chapter 11 bankruptcy. The goal was to halt the thousands of individual jury trials across the country and force all claimants into a single bankruptcy court. From J&J’s perspective, this would cap its financial exposure and create a more predictable process for resolving claims. The company argued it was a more efficient and equitable way to compensate claimants, though plaintiffs’ lawyers widely condemned it as an attempt by a solvent multi-billion dollar corporation to abuse the bankruptcy system and avoid accountability.
Why the Bankruptcy Gambit Failed
The strategy ultimately unraveled after repeated scrutiny from the courts. J&J made three separate attempts to resolve the cases through its subsidiary's bankruptcy, and each one failed. Federal appeals courts repeatedly rejected the filings on a fundamental basis: neither J&J nor its subsidiary was actually in the kind of financial distress that bankruptcy law is designed to protect. The courts noted that J&J, with its immense resources, had guaranteed it would cover LTL Management's liabilities, meaning the subsidiary was never truly at risk of insolvency. The third and final bankruptcy attempt was dismissed in early 2025, not only for the lack of financial distress but also due to irregularities in how votes were collected from claimants on a proposed settlement plan. With the bankruptcy pathway definitively closed, the floodgates for individual trials were set to reopen.
A Shift Toward Negotiation
The collapse of its bankruptcy strategy left Johnson & Johnson facing the prospect of fighting unpredictable, expensive, and reputation-damaging jury trials one by one across the country. While the company continued to maintain that its talc products were safe and did not cause cancer, the legal reality had changed. Adding to the complexity, J&J’s negotiating position was recently strengthened by a significant court ruling that cast doubt on the ability of plaintiffs' experts to scientifically prove that talc specifically caused ovarian cancer in individual cases. This development put pressure on the plaintiffs, creating a new dynamic where both sides had a powerful incentive to come to the table. For J&J, negotiation offered a final, definitive end to the litigation. For claimants, it provided a path to compensation without the risk and delay of further trials. This convergence of interests is what ultimately moved the case out of bankruptcy court and into direct negotiation.
